Morgan Stanley lowered the firm’s price target on Fresenius Medical (FMS) to EUR 39 from EUR 41 and keeps an Underweight rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Reports Strong Q3 2025 Growth
- Fresenius Medical Care Reports Strong Q3 Earnings
- Fresenius Medical reports Q3 adjusted EPS EUR1.10 vs. EUR0.81 last year
- Fresenius Medical still sees 2025 revenue growth in low-single digits
- Fresenius Medical Care Reports Strong Q3 2025 Results and Strategic Progress